EuroBiotech: More Articles of Note


> Juvenescence told Longevity.Technology it has delayed its planned IPO from this year to the second half of 2020. The company now plans to raise a series C round before listing on a U.S. stock exchange. Article

> The FDA accepted DBV Technologies’ application for approval of Viaskin Peanut. The acceptance comes almost 10 months after DBV withdrew its original filing. Release 

> Bavarian Nordic began a phase 1 trial of a vaccine candidate against the equine encephalitis virus. Topline data from the 45-subject study are due next year. Statement 


Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

> The FDA granted fast-track designation to Mereo BioPharma’s navicixizumab in ovarian cancer. The drug is in phase 1b. Release 

> Galderma said a phase 2 trial “successfully demonstrated the safety and efficacy” of its liquid botulinum toxin type A formulation. A phase 3 trial is due to start soon. Statement 

> Motif Bio revealed it will take “several years” and “tens of millions of dollars” to address the FDA’s request for additional data on its antibiotic iclaprim. Motif wants to find a partner for the trial. Release 

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.